The ideal male contraceptive would be inexpensive, reliable, and reversible. It would need to be long acting but have few side effects. New research published in BioMed Central's open access journal Reproductive Biology and Endocrinology used commercially available therapeutic ultrasound equipment to reduce sperm counts of male rats to levels which would result in infertility in humans.
Ultrasound's potential as a male contraceptive was first reported nearly 40 years ago. However the equipment used is now outdated and no longer available. Researchers from the Department of Pediatrics at the University of North Carolina School of Medicine used these experiments as a starting point to see if modern ultrasound equipment usually used for physical therapy could be used as a male contraceptive.
The team led by James Tsuruta found that by rotating high frequency (3MHz) ultrasound around the testes they were able to cause uniform depletion of germ cells throughout the testes. The best results were seen using two sessions consisting of 15 minutes ultrasound, two days apart. Saline was used to provide conduction between the ultrasound transducer and skin, and the testes were warmed to 37 degrees centigrade. Together this reduced sperm to a Sperm Count Index of zero (3 million motile sperm per cauda epididymis).
The World Health Organization has defined oligospermia (low sperm concentration) as less than 15 million sperm per ml. Dr Tsuruta explained, "Unlike humans, rats remain fertile even with extremely low sperm counts. However, our non-invasive ultrasound treatment reduced sperm reserves in rats far below levels normally seen in fertile men (95% of fertile men have more than 39 million sperm in their ejaculate). However further studies are required to determine how long the contraceptive effect lasts and if it is safe to use multiple times."
Notes to Editors
1. Therapeutic ultrasound as a potential male contraceptive: power, frequency and temperature required to deplete rat testes of meiotic cells and epididymides of sperm determined using a commercially available system
James K Tsuruta, Paul A Dayton, Caterina M Gallippi, Michael G O'Rand, Michael A Streicker, Ryan C Gessner, Thomas S Gregory, Erick JR Silva, Katherine G Hamil, Glenda J Moser and David C Sokal
Reproductive Biology and Endocrinology (in press)
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at email@example.com on the day of publication.
2. Reproductive Biology and Endocrinology (RB&E) is an open access, peer-reviewed, online journal that aims to act as a forum for the dissemination of results from excellent research in the reproductive sciences.
3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.